These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4064046)

  • 41. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells.
    Davidson B; Baekelandt M; Shih IeM
    Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor type and single-cell/mesothelial-like cell pattern of breast carcinoma metastases in pleural and peritoneal effusions.
    Antic T; Gong Y; Sneige N
    Diagn Cytopathol; 2012 Apr; 40(4):311-5. PubMed ID: 22431319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic value of p53 protein in the study of serous effusions.
    Zoppi JA; Pellicer EM; Sundblad AS
    Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The diagnostic role of claudins in serous effusions.
    Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
    Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential diagnosis of malignant and reactive cells from serous effusions: image and texture analysis study.
    García-Bonafé M; Moragas A
    Anal Cell Pathol; 1996 Nov; 12(2):85-98. PubMed ID: 8986293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
    Pinto MM
    Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
    Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
    Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
    Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
    Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytology of experimental mesotheliomas induced with crocidolite asbestos.
    Topov J; Kolev K
    Acta Cytol; 1987; 31(3):369-73. PubMed ID: 3035848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic problems in serous effusions.
    Bedrossian CW
    Diagn Cytopathol; 1998 Aug; 19(2):131-7. PubMed ID: 9702493
    [No Abstract]   [Full Text] [Related]  

  • 51. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytopathology of exocrine pancreatic carcinoma in effusions.
    Di Bonito L; Dudine S; Falconieri G
    Acta Cytol; 1991; 35(3):311-4. PubMed ID: 1710404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
    Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of immunoperoxidase staining in serous effusions.
    Sarker AB; Hoshida Y; Nose S
    Bangladesh Med Res Counc Bull; 1993 Aug; 19(2):33-8. PubMed ID: 8161332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
    Ferrandez-Izquierdo A; Navarro-Fos S; Gonzalez-Devesa M; Gil-Benso R; Llombart-Bosch A
    Diagn Cytopathol; 1994; 10(3):256-62. PubMed ID: 7519540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
    Stevens MW; Leong AS; Fazzalari NL; Dowling KD; Henderson DW
    Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The significance of morphometric methods in cytologic diagnostics: differentiation between mesothelial cells, mesothelioma cells and metastatic adenocarcinoma cells in pleural effusions with special emphasis on chromatin texture.
    Oberholzer M; Ettlin R; Christen H; Gschwind R; Buser M; Rösel F; Lötscher R; Dalquen P
    Anal Cell Pathol; 1991 Jan; 3(1):25-42. PubMed ID: 2001333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.